Clinical Trial: Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases

U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07283315) titled 'Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases' on Dec. 01.

Brief Summary: Evaluating the efficacy and safety of anti-CD19/BCMA CAR-NK Cells in Paediatric B cell-related autoimmune diseases

Study Start Date: Dec. 03

Study Type: INTERVENTIONAL

Condition: Paediatric B Cell-related Autoimmune Diseases Autoimmune Diseases CAR

Intervention: BIOLOGICAL: anti-CD19/BCMA CAR NK cells (KN5601-K)

The study adopted a dose-escalation and expansion study design. All subjects will receive fludarabine/ cyclophosphamide lymphodeple...